Healty volunteer
Conditions
Interventions
Ingestion of supplement containing dihydroquercetin for 12 weeks
Ingestion of placebo without dihydroquercetin for 12 weeks
Sponsors
KSO Corporation
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1)Japanese males aged 30 to 64 years old. 2)Subjects whose BMI are from 25 to 40 kg/m2 3)Subjects whose HOMA-R are higher than 1.6 and ISI level is low. 4)Subjects who can make self-judgment and are voluntarily giving written informed consent
Exclusion criteria
Exclusion criteria: 1)Subjects who use oral medication affecting blood glucose. 2)Subjects who constantly use supplements and/or functional foods (including Food for Specified Health Uses, Food with function claims) affecting blood glucose. 3)Subjects who have declared allergic reaction to ingredients contained in test diets. 4) Subjects who are diabetes (including those who are treated with insulin administration) 5)Subjects who contract or are under treatment or are medical history for serious diseases (e.g.,liver disease, kidney disease, and/or heart disease), thyroid gland disease, adrenal gland disease, and/or metabolic disorder. 6)Subjects who have a chronic disease and use medicines continuously. 7)Subjects who have a history of digestive disease affecting digestion and absorption. 8) Subjects whose fasting blood glucose are above 140 mg/dl. 9)Subjects who are judged as unsuitable for the study based on the results of blood tests by the investigator. 10)Subjects who have donated over 200 mL of blood and/or blood components within the last one month prior to the current study or over 400 mL of blood and/or blood components within the last three months prior to the current study. 11)Subjects who are diagnosed as anemic and not suitable for frequent collection of blood. 12)Subjects who are under treatment for or have a history of drug addiction and/or alcoholism. 13)Subjects who are planning to participate in other clinical studies. 14)Subjects who are judged as unsuitable for the study by the investigator for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ISI(Matsuda Index) | — |
Secondary
| Measure | Time frame |
|---|---|
| HOMA-R, HOMA-beta, glucose, insulin, AUC of glucose and insulin, QUICKI | — |
Countries
Japan
Contacts
Public ContactEiji Yoshikawa
KSO Corporation Sales department
Outcome results
None listed